Clearside Biomedical

Clearside Biomedical EPS Growth

Delisted

The EPS Growth of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 11.44 %. In the previous year, EPS Growth was 3.86 % — a change of 196.31% (higher).

EPS Growth

11.44 %

YoY

196.31%

Last updated:

EPS Growth of Clearside Biomedical is 2024 11.44 % . EPS Growth of Clearside Biomedical was 2023 3.86 % . It decreases by 196.31% higher compared to the previous year.

The Clearside Biomedical EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2017
-127.69 USD
Jan 1, 2018
-15.62 USD
Jan 1, 2019
70.08 USD
Jan 1, 2020
51.45 USD
Jan 1, 2021
101.53 USD
Jan 1, 2022
-9,211.11 USD
Jan 1, 2023
3.86 USD
Jan 1, 2024
11.44 USD
The Clearside Biomedical EPS Growth history
YEAREPS GrowthYoY
11.44 %+196.31%
3.86 %-100.04%
-9,211.11 %-9,172.02%
101.53 %+97.35%
51.45 %-26.59%
70.08 %-548.60%
-15.62 %-87.77%
-127.69 %+831.77%
-13.70 %-81.25%
-73.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

EPS Growth of Clearside Biomedical is 11.44 % in 2024.

On Eulerpool you can find the complete historical development of EPS Growth Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clearside Biomedical

All Key Metrics — Clearside Biomedical